Patent · US Active

Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use

US10576141B2 · kind B2 · utility

0Cited by

0References

12Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Ariane Volkmann · Andechs, DE
Robin Steigerwald · Munich, DE
Hubertus Hochrein · Munich, DE
Ulrike Dirmeier · Starnberg, DE
Henning Lauterbach · Eching, DE
Jürgen Hausmann · Gundelfingen, DE

Key dates

Filing date	Sep 3, 2015
Grant date	Mar 3, 2020
Priority date	—
Expiry date	Sep 3, 2035

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.